X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.
Jay Taylor

Jay Taylor Jay Taylor is Vice President of International Advocacy at PhRMA. Prior to Joining PhRMA, Jay was a partner at the international law firm, McDermott, Will & Emery, where he specialized in international trade policy, export controls and Foreign Corrupt Practices Act (FCPA) matters. Previously, Jay served as Associate General Counsel at the Office of the United States Trade Representative (USTR), where he managed and litigated numerous international trade disputes, and drafted and negotiated several free trade agreements. Mr. Taylor received his undergraduate degree from Princeton University, and a law degree from Tulane University.

Recent Posts

Administration’s Special 301 Report highlights deteriorating global environment for biopharmaceutical innovation

By Jay Taylor  |    May 23, 2017
In the latest publication of its annual Special 301 Report, the Office of the U.S. Trade Representative (USTR) brings renewed attention to intellectual property (IP) and market access challenges...   Read More

Compulsory licensing: A misused and abused international trade law

By Jay Taylor  |    May 16, 2017
To maintain our position as the world’s top biopharmaceutical innovator, the U.S. biopharmaceutical industry needs predictable and reliable intellectual property protections. Compulsory licensing...   Read More

Government-imposed price controls threaten innovation and access

By Jay Taylor  |    May 9, 2017
It’s no coincidence that America leads the world in the discovery and development of new lifesaving medicines. U.S. biopharmaceutical innovators invest $60 billion in R&D annually – more than any...   Read More

Illegal trade barriers discriminate against U.S. innovators

By Jay Taylor  |    May 2, 2017
America has long led the world in medical innovation – which brings breakthrough, lifesaving medicines to people around the world, and supplies 4.5 million biopharmaceutical jobs to American...   Read More

Australia is making it harder to protect inventions. That’s bad for American businesses and jobs.

By Jay Taylor  |    April 25, 2017
Bringing a single new medicine to market requires substantial resources over many years. To ensure continued investment in the development of tomorrow’s breakthrough treatments and cures,...   Read More

Trading fair means upholding the law: A focus on patents

By Jay Taylor  |    April 18, 2017
Patents are the linchpin of innovation. In the United States and other countries around the world, they provide temporary protection for new inventions. A fair, stable and predictable patent...   Read More

Enforcing unmet trade obligations protects U.S. innovation

By Jay Taylor  |    April 11, 2017
The United States leads the world in medical innovation, helping patients across the globe access the latest life-saving treatments and cures. Trade agreements with other nations serve as the...   Read More

IP protections found to be critical to life-science innovation and investment

By Jay Taylor  |    April 7, 2016
A new report by the Information Technology and Innovation Foundation (ITIF) has found intellectual property (IP) protections to be crucial to stimulating risk-taking and innovation. The study, How...   Read More

Past free trade agreements provide valuable lessons for future success

By Jay Taylor  |    March 8, 2016
Last week, the Senate Committee on Finance held a hearing to discuss free trade agreement implementation and lessons learned from past agreements. The hearing focused on recent examples where...   Read More

Canada’s innovation opportunity

By Jay Taylor  |    February 11, 2016
Next month’s visit of Prime Minister Justin Trudeau to Washington is a chance to strengthen a vital trade and investment partnership and to resolve problems left over by Canada’s previous...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates